Celltrion Pharm Inc (068760) - Total Assets
Based on the latest financial reports, Celltrion Pharm Inc (068760) holds total assets worth ₩745.80 Billion KRW (≈ $505.42 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Celltrion Pharm Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Celltrion Pharm Inc - Total Assets Trend (2011–2024)
This chart illustrates how Celltrion Pharm Inc's total assets have evolved over time, based on quarterly financial data. See net assets of Celltrion Pharm Inc for net asset value and shareholders' equity analysis.
Celltrion Pharm Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Celltrion Pharm Inc's total assets of ₩745.80 Billion consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩45.48 Billion | 6.8% |
| Accounts Receivable | ₩213.24 Billion | 31.9% |
| Inventory | ₩101.39 Billion | 15.2% |
| Property, Plant & Equipment | ₩222.70 Billion | 33.3% |
| Intangible Assets | ₩6.28 Billion | 0.9% |
| Goodwill | ₩32.91 Billion | 4.9% |
Asset Composition Trend (2011–2024)
This chart illustrates how Celltrion Pharm Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Celltrion Pharm Inc (068760) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celltrion Pharm Inc's current assets represent 58.5% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2024, up from 1.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 31.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 33.3% of total assets.
Celltrion Pharm Inc Competitors by Total Assets
Key competitors of Celltrion Pharm Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
|
Guizhou Sanli Pharmaceutical Co Ltd
SHG:603439
|
China | CN¥2.85 Billion |
Celltrion Pharm Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 1.58 | 1.25 |
| Quick Ratio | 1.16 | 1.06 | 0.95 |
| Cash Ratio | 0.00 | 0.12 | 0.00 |
| Working Capital | ₩176.86 Billion | ₩138.48 Billion | ₩46.03 Billion |
Celltrion Pharm Inc - Advanced Valuation Insights
This section examines the relationship between Celltrion Pharm Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.63 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | ₩669.46 Billion |
| Market Capitalization | $1.18 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Celltrion Pharm Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Celltrion Pharm Inc's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Celltrion Pharm Inc (2011–2024)
The table below shows the annual total assets of Celltrion Pharm Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩669.46 Billion ≈ $453.69 Million |
+4.34% |
| 2023-12-31 | ₩641.64 Billion ≈ $434.83 Million |
+6.99% |
| 2022-12-31 | ₩599.72 Billion ≈ $406.42 Million |
-5.98% |
| 2021-12-31 | ₩637.88 Billion ≈ $432.29 Million |
+16.39% |
| 2020-12-31 | ₩548.07 Billion ≈ $371.42 Million |
+16.37% |
| 2019-12-31 | ₩470.98 Billion ≈ $319.18 Million |
+4.10% |
| 2018-12-31 | ₩452.44 Billion ≈ $306.61 Million |
-3.79% |
| 2017-12-31 | ₩470.27 Billion ≈ $318.69 Million |
-7.79% |
| 2016-12-31 | ₩510.02 Billion ≈ $345.63 Million |
+9.27% |
| 2015-12-31 | ₩466.77 Billion ≈ $316.32 Million |
+13.52% |
| 2014-12-31 | ₩411.16 Billion ≈ $278.64 Million |
+13.78% |
| 2013-12-31 | ₩361.35 Billion ≈ $244.88 Million |
+9.16% |
| 2012-12-31 | ₩331.04 Billion ≈ $224.34 Million |
+53.20% |
| 2011-12-31 | ₩216.08 Billion ≈ $146.43 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more